KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $38.1 million.

  • Jazz Pharmaceuticals' Capital Expenditures rose 11804.84% to $844.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $882.1 million, marking a year-over-year increase of 3006.52%. This contributed to the annual value of $38.1 million for FY2024, which is 58.88% up from last year.
  • Jazz Pharmaceuticals' Capital Expenditures amounted to $38.1 million in FY2024, which was up 58.88% from $24.0 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Capital Expenditures registered a high of $38.1 million during FY2024, and its lowest value of $15.0 million during FY2020.
  • Moreover, its 3-year median value for Capital Expenditures was $29.0 million (2022), whereas its average is $30.4 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first slumped by 62.62% in 2020, then spiked by 84.22% in 2021.
  • Yearly analysis of 5 years shows Jazz Pharmaceuticals' Capital Expenditures stood at $15.0 million in 2020, then spiked by 84.22% to $27.6 million in 2021, then increased by 5.08% to $29.0 million in 2022, then decreased by 17.50% to $24.0 million in 2023, then soared by 58.88% to $38.1 million in 2024.